Company Insights

SDGR customer relationships

Explore interactive graphBrowse insights index
SDGR customer relationship map

Schrodinger (SDGR): Customer Relationships Driving Software-First Drug Discovery

Schrodinger operates a physics-based computational platform that it licenses and subscriptions to biopharma, industrial, academic and government customers, while also partnering on collaborative drug discovery programs that generate milestone and royalty upside. The business monetizes through recurring software sales (short-term contracts and subscriptions), enterprise licensing for high-ACV customers, and program-based milestone revenue that creates lumpy but high-upside financials. Read more at Null Exposure.

How Schrodinger sells value and why customers pay

Schrodinger’s commercial model is software-first and partner-enabled. The company sells two principal forms of access: term licenses that let customers run software on their own hardware and cloud-access subscriptions, both typically sold on annual or near-term contracts. These arrangements create a steady base of software revenue while collaborative programs with pharma add milestone-based upside and align customers to Schrodinger’s platform over multi-year horizons.

  • Contracting posture: The company uses a mix of short-term (one-year typical) contracts and multi‑year enterprise deals; software licensing and subscriptions dominate the Software segment.
  • Customer mix and geography: Sales are global — strong presence in North America, EMEA and APAC — and one customer accounted for roughly 10% of 2024 revenue, an indicator of client concentration risk at the top end.
  • Revenue profile: Recurring software revenue plus milestone/royalty upside from drug discovery collaborations produces predictable base revenue with episodic, material upside.

If you evaluate partner-driven growth strategies, Null Exposure has deeper coverage of Schrodinger’s commercial relationships and risk profile.

Operating constraints and what they imply for investors

Schrodinger’s filings and public commentary reveal several structural constraints that shape deal behavior and financial outcomes:

  • Licensing and subscription orientation. The company explicitly states it delivers software either via product licenses for on-premises use or subscriptions for cloud access; this drives predictable renewal cycles and dependence on license enforcement.
  • Short-term contract cadence for most customers. Many agreements run one year, which increases renewal and retention focus, and raises near-term retention risk relative to long-term lock-ins.
  • Enterprise and government counterparties. Customers include large pharma, universities and government labs — providing credibility and scale but also complex procurement cycles.
  • Geographic diversification but U.S. revenue concentration. Roughly 45% of revenue originates outside the U.S., and the company maintains direct sales operations across major markets; nevertheless, the majority of segment revenue remains U.S.-centric.
  • Material top-customer exposure and an ACV ladder. One customer represented ~10% of 2024 revenue; at scale Schrodinger counts dozens of customers with ACV above $100k and several with ACV above $1m, concentrating risk at the enterprise level.
  • Software segment as the backbone. The Software segment is the revenue anchor; drug discovery programs supplement but do not replace software income in the near term.

These constraints imply a growth model reliant on selling more high-ACV software seats to large pharma and converting program partners into milestone-producing collaborations. The trade-off is clear: faster top-line growth if larger partners adopt LiveDesign and platform services, but increased exposure to timing risk on milestone recognition.

Explore client-level exposures and analytics at Null Exposure for investor-grade detail.

Customer relationships you must know

Below are the customer relationships captured in public reporting and industry commentary. Each entry is summarized plainly with a source citation.

Eli Lilly / TuneLab (Lilly TuneLab)

Schrodinger announced a collaboration in January 2026 to integrate Eli Lilly’s TuneLab AI-driven workflows into Schrodinger’s LiveDesign environment using a privacy-preserving federated learning framework, positioning LiveDesign as a priority interface for participating biotechs. According to multiple news summaries in March 2026, the TuneLab integration underscores Schrodinger’s strategy of embedding its platform into major pharma AI workflows (source: Simply Wall St and BioSpace coverage, January–March 2026 — https://simplywall.st/stocks/us/healthcare/nasdaq-sdgr/schrodinger/news/is-schrdingers-tunelab-ai-integration-reshaping-the-investme/amp; https://www.biospace.com/press-releases/schrodinger-reports-fourth-quarter-and-full-year-2025-financial-results).

Novartis

Novartis entered a multi‑year collaboration that included US$150 million upfront and up to US$2.272 billion in potential milestones, illustrating how major pharma are standardizing on Schrodinger’s platform while leaving investors exposed to milestone timing and realization. Coverage in March 2026 highlighted Novartis as a material strategic partner that validates enterprise uptake of the platform (source: Simply Wall St, March 2026 — https://simplywall.st/stocks/us/healthcare/nasdaq-sdgr/schrodinger/news/is-schrdingers-tunelab-ai-integration-reshaping-the-investme/amp).

Manas AI

Manas AI executed a strategic agreement granting it access to Schrodinger’s computational platform at ultra-large scale, integrating physics-based modeling with Manas AI’s algorithms to improve predictive performance and speed. Company press releases in March 2026 describe this as a platform-scale partnership to accelerate model accuracy and throughput (source: BioSpace press release and FY2025 results commentary, March 2026 — https://www.biospace.com/press-releases/schrodinger-provides-update-on-progress-across-the-business-and-outlines-2026-strategic-priorities; https://www.biospace.com/press-releases/schrodinger-reports-fourth-quarter-and-full-year-2025-financial-results).

What these relationships mean for risk and upside

  • Validation from Big Pharma: Novartis and Eli Lilly collaborations are strategic endorsements that drive adoption among large enterprise customers and support higher ACV deals. This increases revenue potential but also concentrates milestone timing risk.
  • Platform embedding vs. pure licensing: Integrations like TuneLab demonstrate movement from pure licensing toward platform embedding, improving stickiness if LiveDesign becomes the default interface for partner AI workflows.
  • Third‑party algorithm partnerships (Manas AI): Agreements that pair Schrodinger’s physics models with external AI partners accelerate capability and throughput, which supports higher utilization and potential upsell of compute and enterprise packages.

Investment implications and action steps

Schrodinger’s revenue profile is a blend of recurring software cash flows and lumpy, high-upside collaboration milestones. Investors should weigh the benefits of enterprise adoption and platform embedding against the timing uncertainty of milestone recognition and top-customer concentration.

For deeper customer-level exposure analysis and to track how these partnerships translate into revenue and valuation catalysts, visit Null Exposure.

Final recommendation: monitor milestone realization schedules disclosed in company filings and the renewal cadence of high‑ACV licenses; those two levers drive near-term earnings variability and medium-term valuation re‑rating. For ongoing coverage and granular relationship tracking, see Null Exposure.